A potential role for insulin-like growth factor signaling in induction of pluripotent stem cell formation

Growth Hormone and IGF Research

Volumn 20, Issue 6, 2010, Pages 391-398

  Li, Yangxin ^a   Geng, Yong Jian ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Growth; Inducible pluripotent stem cells; Insulin like growth factor; Regenerative medicine; Reprogramming factors; Survival

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN RECEPTOR; STROMAL CELL DERIVED FACTOR 1;

BINDING SITE; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; CELL RENEWAL; CELL SURVIVAL; COMPLEX FORMATION; EMBRYO DEVELOPMENT; GENE EXPRESSION REGULATION; HUMAN; LIGAND BINDING; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; POSTNATAL GROWTH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGENERATIVE MEDICINE; REVIEW; SIGNAL TRANSDUCTION; SOMATIC CELL GENETICS;

ADULT; ADULT STEM CELLS; ANIMALS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, BIOLOGICAL; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELLS; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 78649631618     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2010.09.005     Document Type: Review

References (95)

1. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
2. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., Slukvin, Thomson J.A. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
3. Yamanaka S. Ekiden to iPS cells. Nat. Med. 2009, 15:1145-1148.
4. Belmonte J.C., Ellis J., Hochedlinger K., Yamanaka S. Induced pluripotent stem cells and reprogramming: seeing the science through the hype. Nat. Rev. Genet. 2009, 10:878-883.
5. Yamanaka S. Elite and stochastic models for induced pluripotent stem cell generation. Nature 2009, 460:49-52.
6. Hong H., Takahashi K., Ichisaka T., Aoi T., Kanagawa O., Nakagawa M., Okita K., Yamanaka S. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009, 460:1132-1135.
7. Miura K., Okada Y., Aoi T., Okada A., Takahashi K., Okita K., Nakagawa M., Koyanagi M., Tanabe K., Ohnuki M., Ogawa D., Ikeda E., Okano H., Yamanaka S. Variation in the safety of induced pluripotent stem cell lines. Nat. Biotechnol. 2009, 27:743-745.
8. Hyun I., Hochedlinger K., Jaenisch R., Yamanaka S. New advances in iPS cell research do not obviate the need for human embryonic stem cells. Cell. Stem. Cell. 2007, 1:367-368.
9. Okita K., Nakagawa M., Hyenjong H., Ichisaka T., Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322:949-953.
10. Zhou H., Wu S., Joo J.Y., Zhu S., Han D.W., Lin T., Trauger S., Bien G., Yao S., Zhu Y., Siuzdak G., Scholer H.R., Duan L., Ding S. Generation of induced pluripotent stem cells using recombinant proteins. Cell. Stem. Cell. 2009, 4:381-384.
11. Lin T., Ambasudhan R., Yuan X., Li W., Hilcove S., Abujarour R., Lin X., Hahm H.S., Hao E., Hayek A., Ding S. A chemical platform for improved induction of human iPSCs. Nat. Meth. 2009, 6:805-808.
12. Xu Y., Shi Y., Ding S. A chemical approach to stem-cell biology and regenerative medicine. Nature 2008, 453:338-344.
13. Esteban M.A., Wang T., Qin B., Yang J., Qin D., Cai J., Li W., Weng Z., Chen J., Ni S., Chen K., Li Y., Liu X., Xu J., Zhang S., Li F., He W., Labuda K., Song Y., Peterbauer A., Wolbank S., Redl H., Zhong M., Cai D., Zeng L., Pei D. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell. Stem. Cell. 2010, 6:71-79.
14. LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 1995, 16:143-163.
15. Stewart C.E., Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol. Rev. 1996, 76:1005-1026.
16. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16:3-34.
17. Le Roith D., Bondy C., Yakar S., Liu J.L., Butler A. The somatomedin hypothesis: 2001. Endocr. Rev. 2001, 22:53-74.
18. Delafontaine P., Song Y.H., Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler. Thromb. Vasc. Biol. 2004, 24:435-444.
19. Li Y., Higashi Y., Itabe H., Song Y.H., Du J., Delafontaine P. Insulin-like growth factor-1 receptor activation inhibits oxidized LDL-induced cytochrome C release and apoptosis via the phosphatidylinositol 3 kinase/Akt signaling pathway. Arterioscler. Thromb. Vasc. Biol. 2003, 23:2178-2184.
20. Santini M.P., Tsao L., Monassier L., Theodoropoulos C., Carter J., Lara-Pezzi E., Slonimsky E., Salimova E., Delafontaine P., Song Y.H., Bergmann M., Freund C., Suzuki K., Rosenthal N. Enhancing repair of the mammalian heart. Circ. Res. 2007, 100:1732-1740.
21. Bendall S.C., Stewart M.H., Menendez P., George D., Vijayaragavan K., Werbowetski-Ogilvie T., Ramos-Mejia V., Rouleau A., Yang J., Bosse M., Lajoie G., Bhatia M. IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature 2007, 448:1015-1021.
22. Wang L., Schulz T.C., Sherrer E.S., Dauphin D.S., Shin S., Nelson A.M., Ware C.B., Zhan M., Song C.Z., Chen X., Brimble S.N., McLean A., Galeano M.J., Uhl E.W., D'Amour K.A., Chesnut J.D., Rao M.S., Blau C.A., Robins A.J. Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling. Blood 2007, 110:4111-4119.
23. Li Y., Yu X., Lin S., Li X., Zhang S., Song Y.H. Insulin-like growth factor 1 enhances the migratory capacity of mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2007, 356:780-784.
24. Thum T., Hoeber S., Froese S., Klink I., Stichtenoth D.O., Galuppo P., Jakob M., Tsikas D., Anker S.D., Poole-Wilson P.A., Borlak J., Ertl G., Bauersachs J. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ. Res. 2007, 100:434-443.
25. Torella D., Rota M., Nurzynska D., Musso E., Monsen A., Shiraishi I., Zias E., Walsh K., Rosenzweig A., Sussman M.A., Urbanek K., Nadal-Ginard B., Kajstura J., Anversa P., Leri A. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ. Res. 2004, 94:514-524.
26. Padin-Iruegas M.E., Misao Y., Davis M.E., Segers V.F., Esposito G., Tokunou T., Urbanek K., Hosoda T., Rota M., Anversa P., Leri A., Lee R.T., Kajstura J. Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction. Circulation 2009, 120:876-887.
27. Fleissner F., Thum T. The IGF-1 receptor as a therapeutic target to improve endothelial progenitor cell function. Mol. Med. 2008, 14:235-237.
28. Huang Y.H., Chin C.C., Ho H.N., Chou C.K., Shen C.N., Kuo H.C., Wu T.J., Wu Y.C., Hung Y.C., Chang C.C., Ling T.Y. Pluripotency of mouse spermatogonial stem cells maintained by IGF-1-dependent pathway. FASEB J. 2009, 23:2076-2087.
29. Chen L., Khillan J.S. A novel signaling by vitamin A/retinol promotes self renewal of mouse ES cells by activating PI3K/Akt signaling pathway via IGF-1 receptor. Stem. Cells. 2009.
30. Nguyen T.T., Sheppard A.M., Kaye P.L., Noakes P.G. IGF-I and insulin activate mitogen-activated protein kinase via the type 1 IGF receptor in mouse embryonic stem cells. Reproduction 2007, 134:41-49.
31. Haider H., Jiang S., Idris N.M., Ashraf M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ. Res. 2008, 103:1300-1308.
32. Ponte A.L., Marais E., Gallay N., Langonne A., Delorme B., Herault O., Charbord P., Domenech J. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem. Cells. 2007, 25:1737-1745.
33. Kimber S.J., Sneddon S.F., Bloor D.J., El-Bareg A.M., Hawkhead J.A., Metcalfe A.D., Houghton F.D., Leese H.J., Rutherford A., Lieberman B.A., Brison D.R. Expression of genes involved in early cell fate decisions in human embryos and their regulation by growth factors. Reproduction 2008, 135:635-647.
34. Moverare-Skrtic S., Svensson J., Karlsson M.K., Orwoll E., Ljunggren O., Mellstrom D., Ohlsson C. Serum insulin-like growth factor-I concentration is associated with leukocyte telomere length in a population-based cohort of elderly men. J. Clin. Endocrinol. Metab. 2009.
35. Gonzalez A., Rota M., Nurzynska D., Misao Y., Tillmanns J., Ojaimi C., Padin-Iruegas M.E., Muller P., Esposito G., Bearzi C., Vitale S., Dawn B., Sanganalmath S.K., Baker M., Hintze T.H., Bolli R., Urbanek K., Hosoda T., Anversa P., Kajstura J., Leri A. Activation of cardiac progenitor cells reverses the failing heart senescent phenotype and prolongs lifespan. Circ. Res. 2008, 102:597-606.
36. Wetterau L.A., Francis M.J., Ma L., Cohen P. Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells. J. Clin. Endocrinol. Metab. 2003, 88:3354-3359.
37. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J. Med. 1997, 336:633-640.
38. LeRoith D., Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3:302-310.
39. Denley A., Bonython E.R., Booker G.W., Cosgrove L.J., Forbes B.E., Ward C.W., Wallace J.C. Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol. Endocrinol. 2004, 18:2502-2512.
40. LeRoith D., Roberts C.T. The insulin-like growth factor system and cancer. Cancer Lett. 2003, 195:127-137.
41. Baker J., Liu J.P., Robertson E.J., Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993, 75:73-82.
42. Daughaday W.H., Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev. 1989, 10:68-91.
43. Blanquart C., Achi J., Issad T. Characterization of IRA/IRB hybrid insulin receptors using bioluminescence resonance energy transfer. Biochem. Pharmacol. 2008, 76:873-883.
44. Cascieri M.A., Chicchi G.G., Applebaum J., Hayes N.S., Green B.G., Bayne M.L. Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor. Biochemistry 1988, 27:3229-3233.
45. Schneider M.R., Lahm H., Wu M., Hoeflich A., Wolf E. Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins. FASEB J. 2000, 14:629-640.
46. Sakai K., Busby W.H., Clarke J.B., Clemmons D.R. Tissue transglutaminase facilitates the polymerization of insulin-like growth factor-binding protein-1 (IGFBP-1) and leads to loss of IGFBP-1's ability to inhibit insulin-like growth factor-I-stimulated protein synthesis. J. Biol. Chem. 2001, 276:8740-8745.
47. Mukherjee A., Rotwein P. Insulin-like growth factor-binding protein-5 inhibits osteoblast differentiation and skeletal growth by blocking insulin-like growth factor actions. Mol. Endocrinol. 2008, 22:1238-1250.
48. Bartling B., Koch A., Simm A., Scheubel R., Silber R.E., Santos A.N. Insulin-like growth factor binding proteins-2 and -4 enhance the migration of human CD34-/CD133+ hematopoietic stem and progenitor cells. Int. J. Mol. Med. 2010, 25:89-96.
49. Kielczewski J.L., Jarajapu Y.P., McFarland E.L., Cai J., Afzal A., Li Calzi S., Chang K.H., Lydic T., Shaw L.C., Busik J., Hughes J., Cardounel A.J., Wilson K., Lyons T.J., Boulton M.E., Mames R.N., Chan-Ling T., Grant M.B. Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circ. Res. 2009, 105:897-905.
50. Song Y.H., Li Y., Du J., Mitch W.E., Rosenthal N., Delafontaine P. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J. Clin. Invest. 2005, 115:451-458.
51. Yu X.Y., Geng Y.J., Li X.H., Lin Q.X., Shan Z.X., Lin S.G., Song Y.H., Li Y. The effects of mesenchymal stem cells on c-kit up-regulation and cell-cycle re-entry of neonatal cardiomyocytes are mediated by activation of insulin-like growth factor 1 receptor. Mol. Cell. Biochem. 2009, 332:25-32.
52. Yu X.Y., Song Y.H., Geng Y.J., Lin Q.X., Shan Z.X., Lin S.G., Li Y. Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1. Biochem. Biophys. Res. Commun. 2008, 376:548-552.
53. Li Y., Wu H., Khardori R., Song Y.H., Lu Y.W., Geng Y.J. Insulin-like growth factor-1 receptor activation prevents high glucose-induced mitochondrial dysfunction, cytochrome-c release and apoptosis. Biochem. Biophys. Res. Commun. 2009, 384:259-264.
54. LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 1995, 16:143-163.
55. Liu J.P., Baker J., Perkins A.S., Robertson E.J., Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993, 75:59-72.
56. Sell C., Dumenil G., Deveaud C., Miura M., Coppola D., DeAngelis T., Rubin R., Efstratiadis A., Baserga R. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol. 1994, 14:3604-3612.
57. Cicalese A., Bonizzi G., Pasi C.E., Faretta M., Ronzoni S., Giulini B., Brisken C., Minucci S., Di Fiore P.P., Pelicci P.G. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009, 138:1083-1095.
58. Banito A., Rashid S.T., Acosta J.C., Li S., Pereira C.F., Geti I., Pinho S., Silva J.C., Azuara V., Walsh M., Vallier L., Gil J. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev. 2009, 23:2134-2139.
59. Utikal J., Polo J.M., Stadtfeld M., Maherali N., Kulalert W., Walsh R.M., Khalil A., Rheinwald J.G., Hochedlinger K. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009, 460:1145-1148.
60. Li H., Collado M., Villasante A., Strati K., Ortega S., Canamero M., Blasco M.A., Serrano M. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009, 460:1136-1139.
61. Kawamura T., Suzuki J., Wang Y.V., Menendez S., Morera L.B., Raya A., Wahl G.M., Belmonte J.C. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009, 460:1140-1144.
62. Marion R.M., Strati K., Li H., Murga M., Blanco R., Ortega S., Fernandez-Capetillo O., Serrano M., Blasco M.A. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009, 460:1149-1153.
63. Kavurma M.M., Figg N., Bennett M.R., Mercer J., Khachigian L.M., Littlewood T.D. Oxidative stress regulates IGF1R expression in vascular smooth-muscle cells via p53 and HDAC recruitment. Biochem. J. 2007, 407:79-87.
64. Werner H., Karnieli E., Rauscher F.J., LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl Acad. Sci. USA 1996, 93:8318-8323.
65. Sarfstein R., Maor S., Reizner N., Abramovitch S., Werner H. Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer. Mol. Cell. Endocrinol. 2006, 252:241-246.
66. Feng Z. p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold. Spring Harb. Perspect. Biol. 2010, 2:a001057.
67. Pan G., Thomson J.A. Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res. 2007, 17:42-49.
68. Baserga R., Hongo A., Rubini M., Prisco M., Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta 1997, 1332:F105-F126.
69. Banskota N.K., Taub R., Zellner K., King G.L. Insulin, insulin-like growth factor I and platelet-derived growth factor interact additively in the induction of the protooncogene c-myc and cellular proliferation in cultured bovine aortic smooth muscle cells. Mol. Endocrinol. 1989, 3:1183-1190.
70. Banskota N.K., Taub R., Zellner K., Olsen P., King G.L. Characterization of induction of protooncogene c-myc and cellular growth in human vascular smooth muscle cells by insulin and IGF-I. Diabetes 1989, 38:123-129.
71. Cox J.L., Rizzino A. Induced pluripotent stem cells: what lies beyond the paradigm shift. Exp. Biol. Med. Maywood. 2010, 235:148-158.
72. Sun L.Y., D'Ercole A.J. Insulin-like growth factor-I stimulates histone H3 and H4 acetylation in the brain in vivo. Endocrinology 2006, 147:5480-5490.
73. Marion R.M., Strati K., Li H., Tejera A., Schoeftner S., Ortega S., Serrano M., Blasco M.A. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell 2009, 4:141-154.
74. Zhao R., Daley G.Q. From fibroblasts to iPS cells: induced pluripotency by defined factors. J. Cell. Biochem. 2008, 105:949-955.
75. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
76. Werner C., Hanhoun M., Widmann T., Kazakov A., Semenov A., Poss J., Bauersachs J., Thum T., Pfreundschuh M., Muller P., Haendeler J., Bohm M., Laufs U. Effects of physical exercise on myocardial telomere-regulating proteins, survival pathways, and apoptosis. J. Am. Coll. Cardiol. 2008, 52:470-482.
77. Yoshida Y., Takahashi K., Okita K., Ichisaka T., Yamanaka S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell 2009, 5:237-241.
78. Urbich C., Aicher A., Heeschen C., Dernbach E., Hofmann W.K., Zeiher A.M., Dimmeler S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J. Mol. Cell. Cardiol. 2005, 39:733-742.
79. Sanchez C., Oskowitz A., Pochampally R.R. Epigenetic reprogramming of IGF1 and leptin genes by serum deprivation in multipotential mesenchymal stromal cells. Stem Cells 2009, 27:375-382.
80. Eliasz S., Liang S., Chen Y., De Marco M.A., Machek O., Skucha S., Miele L., Bocchetta M. Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene 2010, 29:2488-2498.
81. Melton C., Judson R.L., Blelloch R. Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Nature 2010, 463:621-626.
82. Slack F.J. Stem cells: Big roles for small RNAs. Nature 2010, 463:616.
83. Mallanna S.K., Rizzino A. Emerging roles of microRNAs in the control of embryonic stem cells and the generation of induced pluripotent stem cells. Dev. Biol. 2010, 344:16-25.
84. Sachdeva M., Zhu S., Wu F., Wu H., Walia V., Kumar S., Elble R., Watabe K., Mo Y.Y. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl Acad. Sci. USA 2009, 106:3207-3212.
85. Lin C.H., Jackson A.L., Guo J., Linsley P.S., Eisenman R.N. Myc-regulated microRNAs attenuate embryonic stem cell differentiation. EMBO J. 2009, 28:3157-3170.
86. Sato N., Meijer L., Skaltsounis L., Greengard P., Brivanlou A.H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med. 2004, 10:55-63.
87. Korkaya H., Paulson A., Charafe-Jauffret E., Ginestier C., Brown M., Dutcher J., Clouthier S.G., Wicha M.S. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009, 7:e1000121.
88. Valdimarsdottir G., Mummery C. Functions of the TGFbeta superfamily in human embryonic stem cells. APMIS 2005, 113:773-789.
89. Vallier L., Reynolds D., Pedersen R.A. Nodal inhibits differentiation of human embryonic stem cells along the neuroectodermal default pathway. Dev. Biol. 2004, 275:403-421.
90. Elliot S.J., Karl M., Berho M., Xia X., Pereria-Simon S., Espinosa-Heidmann D., Striker G.E. Smoking induces glomerulosclerosis in aging estrogen-deficient mice through cross-talk between TGF-beta1 and IGF-I signaling pathways. J. Am. Soc. Nephrol. 2006, 17:3315-3324.
91. Hall J., Guo G., Wray J., Eyres I., Nichols J., Grotewold L., Morfopoulou S., Humphreys P., Mansfield W., Walker R., Tomlinson S., Smith A. Oct4 and LIF/Stat3 additively induce Kruppel factors to sustain embryonic stem cell self-renewal. Cell. Stem. Cell. 2009, 5:597-609.
92. Coffer P.J., van Puijenbroek A., Burgering B.M., Klop-de Jonge M., Koenderman L., Bos J.L., Kruijer W. Insulin activates Stat3 independently of p21ras-ERK and PI-3K signal transduction. Oncogene 1997, 15:2529-2539.
93. Zong C.S., Chan J., Levy D.E., Horvath C., Sadowski H.B., Wang L.H. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J. Biol. Chem. 2000, 275:15099-15105.
94. Xu J., Wang F., Tang Z., Zhan Y., Zhang J., Yan Q., Xiong Y., Xie X., Wu J., Zhang S. Role of leukaemia inhibitory factor in the induction of pluripotent stem cells in mice. Cell Biol. Int. 2010, 34:791-797.
95. Ji L., Liu Y.X., Yang C., Yue W., Shi S.S., Bai C.X., Xi J.F., Nan X., Pei X.T. Self-renewal and pluripotency is maintained in human embryonic stem cells by co-culture with human fetal liver stromal cells expressing hypoxia inducible factor 1alpha. J. Cell. Physiol. 2009, 221:54-66.